Conducting Research in Residency

Q&A begins
Experts
    • Infectious Disease
    • Infectious Diseases
    • HIV/AIDS
    • Clinical research,epidemiology, clinical trials design and implementation,Statistics
    • Graduate Medical Education
    • Health care policy
    • Internal Medicine Residency
    • Infectious Diseases Fellowship Program Director at Mount Sinai Beth Israel/Morningside/West, Icahn School of Medicine at Mount Sinai

    Georgina Osorio, MD, MPH is an Assistant Professor of Medicine at the Icahn School of Medicine, Mount Sinai Morningside and Mount Sinai West Division of Infectious Disease, Department of Internal Medicine. Dr. Osorio's research focuses on patient navigation and motivational interviewing in HIV/HCV patient population (Clinical Trials Network).

    • Critical Care Medicine
    • Pulmonary Disease
    Assistant Professor, Division of Pulmonary & Critical Care Medicine, University of Washington; Associate Program Director for Research & Scholarship, UW Internal Medicine Residency; Affiliate Investigator, Fred Hutchinson Cancer Research Center
    Assistant Professor, Division of Pulmonary & Critical Care Medicine, University of Washington; Associate Program Director...
    • Associate Program Director, IM Residency at University of Washington

    As pulmonologist and intensivist, my clinical focus is managing complications of cancer therapy.  As a clinician-scholar, I draw from my formal clinical research training to oversee a Research in Residency program and build curricula for future physician-scientists.

    • Neurological Surgery
    • Intraoperative imaging / technology
    • Low and High Grade Gliomas
    • Awake surgery
    • Language Mapping and Motor Mapping
    • Metastatic Brain Cancer
    • Meningiomas
    • Gliomas
    • Brain Tumors
    Dr. Brian Nahed specializes in brain tumors and intraoperative technology.  As the Associate Program Director of the Neurosurgery Residency at MGH, he is focused on education and mentoring of residents and medical students.
    Dr. Brian Nahed specializes in brain tumors and intraoperative technology.  As the Associate Program Director of the...
    • Associate Professor of Neurosurgery & Associate Director, Neurosurgery Program at Massachusetts General Hospital and Harvard Medical School

    Dr. Brian Nahed is a neurosurgeon specializing in brain tumors (glioblastoma, gliomas (low grade and high grade), metastatic brain tumors, and meningiomas) as well as Spinal Disorders. Dr. Nahed specializes in brain tumors of the eloquent cortex (language and motor areas of the brain) which require awake surgery, language and motor mapping, and subcortical stimulation. Born in New York, Dr. Nahed attended UCLA where he majored in Neuroscience, graduating Phi Beta Kappa and with the department's Highest Honors. He attended the Yale School of Medicine where he was awarded the Doris Duke Clinical Research Fellowship and graduated with honors. Dr. Nahed completed his internship and neurosurgery residency at the Massachusetts General Hospital; where Dr. Nahed also completed a postdoctoral fellowship with Drs. Daniel Haber and Shyamala Maheswaran in the MGH Cancer Center. Dr. Brian Nahed was recruited to the MGH Department of Neurosurgery and Brain Tumor Center in 2011. As an Associate Professor at Harvard Medical School, Dr. Brian Nahed's research focuses on developing the first blood based test to diagnose and monitor brain tumors. In collaboration with Drs. Haber, Maheswaran, and Stott, Dr. Nahed recently published the first evidence of circulating tumor cells in the blood of patients with glioma. Dr. Nahed is actively enrolling patients into his translational clinical research study. Dr. Brian Nahed serves as the Associate Director of the MGH Neurosurgery Residency Program. He serves on the Executive Committee of the Congress of Neurological Surgeons and the CNS/AANS section on Tumors. He is an active member of the American Association of Neurological Surgeons and Council State Neurological Societies. Dr. Nahed is focused on education and socioeconomic issues in neurosurgery. He also serves as a neurotrauma consultant for the National Football League (NFL).

    • Pediatric Infectious Diseases
    • Professor of Pediatrics in Infectious Diseases at University of Tennessee School of Medicine

    Dr. DeVincenzo is currently VP of Translational Biology at Enanta Pharmacueticals.  He recently completed a 25 year role as a Practicing Pediatric Infectious Diseases Specialist at Le Bonheur Children’s Hospital in Memphis Tennessee and Professor of Pediatrics and Professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research has focused on understanding the pathogenesis of respiratory syncytial virus (RSV) directly in children and using this understanding to develop therapeutic and prevention strategies against this virus.  He is the author of over 250 original published abstracts and papers on this subject.  Dr. DeVincenzo’s research initially focused on the immunogenetics of RSV disease and the interplay between viral dynamics and RSV disease severity in infants.  Subsequently, his research focus shifted to apply this knowledge of RSV dynamics to the development of novel therapeutics for RSV.  His development of RNA interference-based therapeutics for RSV has shown recent success.  For his groundbreaking proof of concept work applying RNA interference concepts to develop human therapeutics, Dr. DeVincenzo’s study was listed as one of the most influential papers in medicine in 2010 (American Society for Microbiology).  From this work, Dr. DeVincenzo set about developing antivirals and vaccines using a variety of approaches for RSV; from conception to proof of concept clinical trials through several academic, foundation, and industry pathways.  He and colleagues have demonstrated the first evidence that treating an established RSV infection in humans can lower the viral load and result in reduced disease. He has subsequently extended similar proofs of human antiviral RSV-therapeutic efficacy for four other novel antiviral compounds with different mechanisms of action.  He is currently progressing several international RSV antiviral programs into pediatric and adult populations in his new role at Enanta Pharmaceuticals.

    Dr. DeVincenzo received his undergraduate degree in biology from Stanford University, and then attended Vanderbilt Medical School where he became interested in pediatric infectious diseases and earned his MD degree.  His internship and residency were completed at U.C.L.A Center for Health Sciences.  After finishing his pediatrics training, Dr. DeVincenzo studied tropical medicine at Walter Reed and practiced general medicine in Central Africa before starting formal training in Pediatric Infectious Diseases at Boston Children’s Hospital and Harvard Medical School.  During this time, he also completed a research fellowship at the Dana Farber Cancer Institute working with his mentor, George Siber, in developing passive antibody approaches for RSV treatment and prevention.  Dr. DeVincenzo has conducted numerous clinical and translational trials in children refining the pathogenesis of RSV and defining the role of prevention and therapeutic applications of monoclonal antibodies targeting RSV in infants and the immune suppressed.  He ran an active NIH-funded academic laboratory studying RSV and other respiratory viruses for over a decade, and has received numerous honors for his research including honorary induction into Alpha Omega Alpha National Medical Honor Society (2009), the Healthcare Heroes Award for innovation (2008), and the best advance in Therapy and Prevention of a Microbial Disease (ICAAC 2007). Dr. DeVincenzo was also the medical director of the University affiliated Le Bonheur Children’s Hospital Diagnostic Virology Laboratory and the Methodist/Le Bonheur Molecular Diagnostics Laboratory. He is a board certified pediatric infectious disease specialist, has lectured nationally and internationally, and has received awards for clinical teaching of medical students, residents, and fellows.

Powered by Medstro